BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 33168005)

  • 21. Mesenchymal Stem Cells Successfully Deliver Oncolytic Virotherapy to Diffuse Intrinsic Pontine Glioma.
    Chastkofsky MI; Pituch KC; Katagi H; Zannikou M; Ilut L; Xiao T; Han Y; Sonabend AM; Curiel DT; Bonner ER; Nazarian J; Horbinski CM; James CD; Saratsis AM; Hashizume R; Lesniak MS; Balyasnikova IV
    Clin Cancer Res; 2021 Mar; 27(6):1766-1777. PubMed ID: 33272983
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Convection-Enhanced Delivery of Enhancer of Zeste Homolog-2 (EZH2) Inhibitor for the Treatment of Diffuse Intrinsic Pontine Glioma.
    Sasaki T; Katagi H; Goldman S; Becher OJ; Hashizume R
    Neurosurgery; 2020 Nov; 87(6):E680-E688. PubMed ID: 32674144
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of new therapeutic targets and natural compounds against diffuse intrinsic pontine glioma (DIPG).
    Chen J; Lin Z; Barrett L; Dai L; Qin Z
    Bioorg Chem; 2020 Jun; 99():103847. PubMed ID: 32311581
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diffusion-weighted MRI derived apparent diffusion coefficient identifies prognostically distinct subgroups of pediatric diffuse intrinsic pontine glioma.
    Lober RM; Cho YJ; Tang Y; Barnes PD; Edwards MS; Vogel H; Fisher PG; Monje M; Yeom KW
    J Neurooncol; 2014 Mar; 117(1):175-82. PubMed ID: 24522717
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ACVR1 R206H cooperates with H3.1K27M in promoting diffuse intrinsic pontine glioma pathogenesis.
    Hoeman CM; Cordero FJ; Hu G; Misuraca K; Romero MM; Cardona HJ; Nazarian J; Hashizume R; McLendon R; Yu P; Procissi D; Gadd S; Becher OJ
    Nat Commun; 2019 Mar; 10(1):1023. PubMed ID: 30833574
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Developing chemotherapy for diffuse pontine intrinsic gliomas (DIPG).
    Gwak HS; Park HJ
    Crit Rev Oncol Hematol; 2017 Dec; 120():111-119. PubMed ID: 29198324
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of Novel RAS Signaling Therapeutic Vulnerabilities in Diffuse Intrinsic Pontine Gliomas.
    Koncar RF; Dey BR; Stanton AJ; Agrawal N; Wassell ML; McCarl LH; Locke AL; Sanders L; Morozova-Vaske O; Myers MI; Hamilton RL; Carcaboso AM; Kohanbash G; Hu B; Amankulor NM; Felker J; Kambhampati M; Nazarian J; Becher OJ; James CD; Hashizume R; Broniscer A; Pollack IF; Agnihotri S
    Cancer Res; 2019 Aug; 79(16):4026-4041. PubMed ID: 31201162
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tenascin-C expression contributes to pediatric brainstem glioma tumor phenotype and represents a novel biomarker of disease.
    Qi J; Esfahani DR; Huang T; Ozark P; Bartom E; Hashizume R; Bonner ER; An S; Horbinski CM; James CD; Saratsis AM
    Acta Neuropathol Commun; 2019 May; 7(1):75. PubMed ID: 31092287
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intraarterial delivery of bevacizumab and cetuximab utilizing blood-brain barrier disruption in children with high-grade glioma and diffuse intrinsic pontine glioma: results of a phase I trial.
    McCrea HJ; Ivanidze J; O'Connor A; Hersh EH; Boockvar JA; Gobin YP; Knopman J; Greenfield JP
    J Neurosurg Pediatr; 2021 Aug; 28(4):371-379. PubMed ID: 34359048
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-tumor efficacy of anti-GD2 CAR NK-92 cells in diffuse intrinsic pontine gliomas.
    Zuo P; Li Y; He C; Wang T; Zheng X; Liu H; Wu Z; Zhang J; Liao X; Zhang L
    Front Immunol; 2023; 14():1145706. PubMed ID: 37251413
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preclinical evaluation of dasatinib alone and in combination with cabozantinib for the treatment of diffuse intrinsic pontine glioma.
    Truffaux N; Philippe C; Paulsson J; Andreiuolo F; Guerrini-Rousseau L; Cornilleau G; Le Dret L; Richon C; Lacroix L; Puget S; Geoerger B; Vassal G; Östman A; Grill J
    Neuro Oncol; 2015 Jul; 17(7):953-64. PubMed ID: 25534822
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fimepinostat Impairs NF-κB and PI3K/AKT Signaling and Enhances Gemcitabine Efficacy in H3.3K27M-Diffuse Intrinsic Pontine Glioma.
    Wang D; Yan K; Yu H; Li H; Zhou W; Hong Y; Guo S; Wang Y; Xu C; Pan C; Tang Y; Liu N; Wu W; Zhang L; Xi Q
    Cancer Res; 2024 Feb; 84(4):598-615. PubMed ID: 38095539
    [TBL] [Abstract][Full Text] [Related]  

  • 33. TP53 wild-type/PPM1D mutant diffuse intrinsic pontine gliomas are sensitive to a MDM2 antagonist.
    Xu C; Liu H; Pirozzi CJ; Chen LH; Greer PK; Diplas BH; Zhang L; Waitkus MS; He Y; Yan H
    Acta Neuropathol Commun; 2021 Nov; 9(1):178. PubMed ID: 34732238
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase I/II study of ribociclib following radiation therapy in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG).
    DeWire M; Fuller C; Hummel TR; Chow LML; Salloum R; de Blank P; Pater L; Lawson S; Zhu X; Dexheimer P; Carle AC; Kumar SS; Drissi R; Stevenson CB; Lane A; Breneman J; Witte D; Jones BV; Leach JL; Fouladi M
    J Neurooncol; 2020 Sep; 149(3):511-522. PubMed ID: 33034839
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Potent anti-tumor efficacy of palbociclib in treatment-naïve H3.3K27M-mutant diffuse intrinsic pontine glioma.
    Sun Y; Sun Y; Yan K; Li Z; Xu C; Geng Y; Pan C; Chen X; Zhang L; Xi Q
    EBioMedicine; 2019 May; 43():171-179. PubMed ID: 31060906
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Post-radiotherapy apparent diffusion coefficient (ADC) in children and young adults with high-grade gliomas and diffuse intrinsic pontine gliomas.
    Carceller F; Jerome NP; Fowkes LA; Khabra K; Mackinnon A; Bautista F; Marshall LV; Vaidya S; Mandeville H; Morgan V; Leach MO; Koh DM
    Pediatr Hematol Oncol; 2019 Mar; 36(2):103-112. PubMed ID: 30978130
    [No Abstract]   [Full Text] [Related]  

  • 37. Phase I trial of panobinostat in children with diffuse intrinsic pontine glioma: A report from the Pediatric Brain Tumor Consortium (PBTC-047).
    Monje M; Cooney T; Glod J; Huang J; Peer CJ; Faury D; Baxter P; Kramer K; Lenzen A; Robison NJ; Kilburn L; Vinitsky A; Figg WD; Jabado N; Fouladi M; Fangusaro J; Onar-Thomas A; Dunkel IJ; Warren KE
    Neuro Oncol; 2023 Dec; 25(12):2262-2272. PubMed ID: 37526549
    [TBL] [Abstract][Full Text] [Related]  

  • 38. OKN-007 decreases tumor necrosis and tumor cell proliferation and increases apoptosis in a preclinical F98 rat glioma model.
    de Souza PC; Balasubramanian K; Njoku C; Smith N; Gillespie DL; Schwager A; Abdullah O; Ritchey JW; Fung KM; Saunders D; Jensen RL; Towner RA
    J Magn Reson Imaging; 2015 Dec; 42(6):1582-91. PubMed ID: 25920494
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Advanced ADC Histogram, Perfusion, and Permeability Metrics Show an Association with Survival and Pseudoprogression in Newly Diagnosed Diffuse Intrinsic Pontine Glioma: A Report from the Pediatric Brain Tumor Consortium.
    Vajapeyam S; Brown D; Billups C; Patay Z; Vezina G; Shiroishi MS; Law M; Baxter P; Onar-Thomas A; Fangusaro JR; Dunkel IJ; Poussaint TY
    AJNR Am J Neuroradiol; 2020 Apr; 41(4):718-724. PubMed ID: 32241771
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Microtubule-Targeting Combined with HDAC Inhibition Is a Novel Therapeutic Strategy for Diffuse Intrinsic Pontine Gliomas.
    Ehteda A; Khan A; Rajakumar G; Vanniasinghe AS; Gopalakrishnan A; Liu J; Tsoli M; Ziegler DS
    Mol Cancer Ther; 2023 Dec; 22(12):1413-1421. PubMed ID: 37683275
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.